bullish
About the Recent Rebound in China Healthcare and the Future Direction (Updated Top Picks)
213 Views18 Oct 2022 08:55
There's catalyst in medical device sector, leading to the recent rebound, but investors should exit in time before the truth is revealed. After the rally, share price in China healthcare will diverge.
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Interpretation of the 20th National Congress of the CPC and the Impact on China Healthcare24 Oct 2022
- China Healthcare Weekly (Oct.21) - Electrophysiology VBP; Orthodontics VBP New Progress; HPV Vaccine23 Oct 2022
- Microport Scientific (853.HK) - Underperformance Would Be the Norm20 Oct 2022
- Russia-Ukraine War Episode 2 - The Balance Could Tilt Again and Its Impact on Healthcare Industry12 Oct 2022
- Wuxi Biologics (2269.HK) - Removed from UVL, but the Crisis Is Not Over11 Oct 2022
- About the CXO Plunge After Biden Signed National Biotechnology and Biomanufacturing Initiative19 Sep 2022
x